The Supreme Court temporarily restored access to the abortion drug mifepristone when dispensed at pharmacies and sent by mail on May 4, 2026 as it considers a lower-court decision in Louisiana’s fight against abortion pills.
The justices were asked to weigh in after the Fifth Circuit Court of Appeals on May 1 granted Louisiana’s request to block a 2023 Food and Drug Administration (FDA) rule that allows mifepristone to be provided by pharmacies and via telehealth. For several days, pregnant people were unable to obtain mifepristone without an in-person doctor’s visit.
Previously, they had been able to get abortion medications through telehealth—including in states with abortion bans.
Danco Laboratories and GenBioPro—the two pharmaceutical companies that manufacture mifepristone—filed emergency petitions with the Court on May 2 asking the justices to block the Fifth Circuit’s ruling.
Today’s order means patients can still get mifepristone by mail or at a pharmacy—for now. Louisiana must respond to the pharma companies’ emergency petitions by May 7. Justice Samuel Alito, who issued the week-long stay, gave the Court a week to consider the parties’ filings, setting a deadline of May 11 at 5 p.m.
The Court’s next steps could fundamentally alter the national abortion access landscape—and upend how some patients obtain medication abortion care. Leaving the Fifth Circuit’s stay of the 2023 FDA rule in place would go further than the Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision that ended federal abortion protections by restricting abortion access for the millions of Americans who live in protective states.
How does medication abortion work?
The most common U.S. medication abortion regimen uses two drugs: mifepristone and misoprostol.
First, a patient takes mifepristone, which blocks progesterone and prevents a pregnancy from progressing. Within the next 48 hours, the patient takes four misoprostol pills, which can be taken orally or delivered vaginally. Providers may prescribe additional doses of misoprostol.
Misoprostol causes the uterus to contract and shed its lining, ultimately expelling the pregnancy tissue. The drug is also used to treat stomach ulcers and fibroids, in miscarriage care, and during intrauterine device insertion.
It’s a highly effective method of abortion care: When completed within the first ten weeks of pregnancy, the mifepristone-misoprostol regimen is successful 95 percent of the time. When done in the first nine weeks, an estimated 99 percent of medication abortions are successful.
Medication abortions without mifepristone
While not as effective as the two-drug regimen, misoprostol-only medication abortions can safely and successfully terminate a pregnancy. Misoprostol-exclusive care involves taking three to four doses—for a total of 12 pills—of the drug three to four hours apart, according to Planned Parenthood.
A systematic review of studies on misoprostol-only abortions found that those involving at least three doses worked 87 percent of the time. In a 2023 study published in a Journal of the American Medical Association, 95.3 percent of participants were found to have completed abortion care without procedural intervention after a misoprostol-only course at their one-week follow-up. At their three-week follow-up, 98.6 percent had successfully terminated their pregnancies without procedural intervention.
“Misoprostol alone is an acceptable alternative if mifepristone isn’t available,” Dr. Lisa Hofler, chair of obstetrics and gynecology at the University of New Mexico, told Rewire News Group in May 2025.
Telehealth abortion care is popular
Telehealth abortion care became a lifeline for patients in abortion-restrictive states after the Supreme Court overturned Roe v. Wade in 2022, and recent estimates suggest nearly two-thirds of U.S. abortions are medication abortions. A March 2026 Guttmacher Institute report showed that in 2025, patients in states that ban abortion increasingly turned to telehealth while fewer traveled out-of-state to obtain care.
This shift can be partially attributed to the Biden-era rule change, when the FDA removed a longstanding requirement for mifepristone to be dispensed by a provider in-person.
In October 2025, Louisiana Attorney General Liz Murrill sued the FDA over this rule change, asking a federal district court to declare it unlawful and block its implementation. In February 2026, the district court allowed GenBioPro and Danco Laboratories, the pharmaceutical companies that respectively manufacture generic and name-brand versions of mifepristone, to intervene in the case.
The Fifth Circuit’s May 1 ruling threw abortion access into chaos.
“This ruling is a blueprint for how abortion bans are meant to operate in a post‑Roe country—by reaching across state lines, surveilling pregnant people and their providers, and recasting patients as victims to justify the investigation, arrest, and jail time of providers,” National Institute for Reproductive Health President Christian LoBue said in response to the Fifth Circuit’s ruling.
“Medication abortion is safe, effective, and widely used,” she continued, “and telehealth has been a critical way for patients—especially those in rural areas or who can’t take time off work—to access care.”
This is a developing story. RNG will update this article as the case continues.
The post Abortion Pill Access Is in Limbo. Here’s What’s at Stake—and Your Options. appeared first on Rewire News Group.